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The vaccinia virus virion RNA polymerase that is active in early gene transcription contains a unique subunit encoded by the H4L
gene. Prior studies demonstrated that this protein is required both for early gene transcription initiation and for transcription
termination. Polyclonal antibodies raised against H4L amino acids 1 to 256 prevent both initiation and termination of transcription,
in vitro. Pretreatment of the anti-H4L antibody with a H4L fragment containing amino acids 1 to 99 prevents antibody inhibition of
both steps, mapping the inhibitory antibody-binding site to this region. A combination of immunoprecipitation and competition
studies of antibody binding to wild-type and site-specific mutations of H4L1–195 mapped the strong epitope to a site that includes
Y18. H4L fragments containing an Y18Amutation exhibit diminished ability to block antibody inhibition of transcription initiation and
termination. Antibodies inhibit preinitiation complex (PIC) formation but not the activity of preformed PICs, indicating that this region
of H4L interacts with one or more factors during active PIC formation. Furthermore, isolated H4L1–195 directly inhibits PIC activity,
supporting this model. Anti-H4L antibody inhibition of transcription termination is only observed in the absence of the essentialINTRODUCTION
Vaccinia virus, a member of the poxvirus family, pos-
sesses a linear double-stranded DNA genome, yet con-
ducts its replication cycle exclusively in the cytoplasm of
infected cells. Rather than depend upon nuclear machin-
ery, poxviruses encode the enzymes required for viral
gene transcription, mRNA processing, and genome rep-
lication (Moss, 2001). Investigations of the poxvirus path-
ways of gene expression and DNA replication provide a
unique perspective on enzymatic and regulatory mech-
anisms employed in these processes.
Poxvirus gene expression can be divided into three
temporal classes (Moss, 1990) that differ in the promoter
sequences (Davison and Moss, 1989a,b; Baldick et al.,
1992) recognized by the viral RNA polymerase and the
virus-encoded and host nuclear factors employed (Gu-
nasinghe et al., 1998; Rosales et al., 1994; Wright et al.,
2001; Zhu et al., 1998). Early genes are transcribed in the
virus core immediately upon infection. Virions possess
two multisubunit forms of RNA polymerase that differ in
subunit composition (Ahn and Moss, 1992; Kane and
Shuman, 1992). The form that is active in early gene
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142transcription has one extra subunit, RAP94, the product
of gene H4L (Ahn and Moss, 1992; Kane and Shuman,
1992). The H4L-deficient RNA polymerase is incapable of
recognizing early promoters, but is able both to catalyze
nonspecific transcription of single-stranded DNA (Ahn et
al., 1994; Ahn and Moss, 1992; Kane and Shuman, 1992)
and to initiate transcription on late promoters, in vitro.
Early gene transcription initiation also requires a het-
erodimeric promoter-binding factor, the vaccinia virus
early gene transcription factor, VETF (Broyles et al.,
1988). VETF has two subunits, the products of genes D6R
and A7L (Broyles and Fesler, 1990; Gershon and Moss,
1990). VETF binds both to an upstream AT-rich promoter
core sequence and to the initiator region (Broyles and Li,
1993; Broyles et al., 1991; Hagler and Shuman, 1992;
Cassetti and Moss, 1996). Presumably, VETF interacts
with one or more subunits of the virion RNA polymerase
stabilizing the preinitiation complex (PIC) and fostering
viral early gene transcription initiation.
Rabbit polyclonal antibodies directed against the N-
terminal 323 or 364 amino acids of H4L inhibit transcrip-
tion, in vitro (Ahn et al., 1994; Deng and Shuman, 1994).
Evidence indicates that the antibodies bind to one or
more epitopes in the N-terminal end of H4L and prevent
the formation of a stable transcription complex. Antisera
do not inhibit transcription elongation, indicating that thistermination cofactor NPH I. In contrast, antibody inhibition
inhibitory antibody and NPH I can bind to H4L at the same ti
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region of H4L is needed for viral transcription initiation
and not elongation (Ahn et al., 1994; Deng and Shuman,of PIC
me. ©
1994). However, antibody supershift analysis demon-
strated that H4L remains associated with the elongating
RNA polymerase in a stable ternary complex (Deng and
Shuman, 1994). It is not clear what role the N-terminal
end of H4L plays in transcription initiation. One reason-
able model posits that H4L directly interacts with VETF
during the formation of the active PIC.
An IgG fraction derived from a polyclonal rabbit anti-
serum raised against the first 256 amino acids of H4L
also inhibits early gene transcription termination (Mo-
hamed and Niles, 2001). Preliminary mapping studies
showed that the region of H4L between amino acids 1
and 195 contains the inhibitory antibody-binding sites.
Inhibition was observed only in transcription extracts
prepared from mutant virus-infected cells that lack the
required termination cofactor nucleoside triphosphate
phosphohydrolase I (NPH I) (Christen et al., 1998; Deng
et al., 1998). NPH I catalyzes ATP hydrolysis only in the
presence of single-stranded DNA. Addition of NPH I
either to a crude cellular extract lacking NPH I or to an
isolated ternary complex prepared from an extract that
lacked NPH I prevented antibody inhibition of termina-
tion (Mohamed and Niles, 2001). Thus, the N-terminal
region of the H4L RNA polymerase subunit plays an
essential role both in early gene transcription initiation
and in transcription termination.
The basis for antibody inhibition of transcription initi-
ation and termination was further investigated. In this
report we demonstrate that inhibitory antibodies raised
against the N-terminal 256 amino acids of H4L bind to
epitopes in N-terminal 99 amino acids. Further mapping
shows that the major epitope in H4L includes amino acid
Y18, which when converted to alanine exhibits de-
creased antibody affinity and decreased ability to block
antibody inhibition of initiation and termination. In addi-
tion, transcription activity of preformed PICs is not inhib-
ited by anti-H4L1–256, confirming that the inhibitory anti-
bodies prevent the formation, not the activity of the
preinitiation complex. Addition of H4L1–195 to the virus-
infected cell extract prior to the template directly inhibits
active PIC formation, indicating that this region of H4L
interacts with one or more factors required for active PIC
assembly. Inhibition of PIC activity is the same whether
PICs are formed in extracts prepared from either wild-
type virus or NPHI-deficient virus-infected cells demon-
strating that the binding of NPHI and the inhibitory anti-
body is not mutually exclusive.
RESULTS
Inhibition of viral early gene transcription by
antibodies directed against the RNA polymerase H4L
subunit
Prior studies showed that antibodies directed against the
N-terminal 323 or 364 amino acids of the H4L subunit
inhibited early gene transcription in vitro (Ahn and Moss,
1992; Deng and Shuman, 1994). To further localize the
region of H4L that is required for RNA synthesis rabbit
polyclonal IgG raised against regions of H4L were purified
and tested for their ability to inhibit formation of an active
preinitiation complex, in vitro. A bead-bound template de-
scribed by Deng et al. (1996) was employed in these stud-
ies, Fig. 1A. The template possesses a strong early pro-
moter, which directs transcription through a 20-bp G-less
cassette that is followed by 3 G residues. RNA synthesis in
the absence of GTP and the presence of 3-O-methyl-GTP
yields a 21-base product that can be identified by gel
electrophoresis, Figs. 1B and 1C. RNA polymerase and
required transcription factors are provided in an extract
prepared from wild-type or temperature-sensitive mutant
virus-infected cells (Condit et al., 1996). To assess the ability
of anti-H4L antibodies to inhibit active PIC formation on an
early promoter, an extract prepared from cells infected at
the nonpermissive temperature with C50 ts mutant virus
that lacks NPH I (Christen et al., 1998) was preincubated
with IgG raised against different regions of H4L. After incu-
bation of the bead-bound template with the antibody-
treated infected cell extract, the template was isolated and
washed to remove loosely bound material. The level of
active PIC was assayed by incubation with ATP, [-32P]CTP,
UTP, and 3-O-methyl-GTP and RNA observed by autora-
diography after gel electrophoresis. In Fig. 1B, it can be
seen that antibodies directed against the N-terminal 256
amino acids of H4L inhibit PIC activity while antibodies
directed against the C-terminal two-thirds of H4L have no
effect. Titration of the antibody revealed that about 100 ng of
crude IgG per reaction results in 50% inhibition of transcrip-
tion activity. The addition of cordycepin 5-triphosphate to
the infected cell extract prior to the antibody preincubation
step does not alter the results, demonstrating that RNA
synthesis is not required during the formation and isolation
of the stable PIC (data not shown).
Inhibitory antibodies recognize epitopes in the N-
terminal 99 amino acids of H4L
In order to ensure that inhibition of PIC activity by
anti-H4L1–256 required recognition of one or more
epitopes in H4L, and to identify the position of the inhib-
itory epitopes in H4L, anti-H4L1–256 was preincubated
with purified H4L fragments prior to testing the anti-
body’s ability to inhibit PIC activity. H4L fragments were
expressed as N-terminal his6 fusions and purified from
Escherichia coli. Preincubation of anti-H4L1–256 with
H4L1–256 showed a concentration-dependent ability to
prevent antibody inhibition of PIC activity. Furthermore,
H4L1–195, H4L1–125, and H4L1–99 also prevented anti-H4L1–256
inhibition of PIC activity, Figs. 2A and 2B. These results
demonstrate that anti-H41–256 recognizes one or more
epitopes in the N-terminal 99 amino acids of H4L, and
that antibody binding inhibits PIC activity.
In order to refine the map position of the inhibitory
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antibody binding site(s) on H4L, direct immunoprecipita-
tion and competition studies were conducted. pCite 4a
derivatives that direct the synthesis of short 35S-met-
labeled H4L fragments were constructed, Fig. 3A. The
ability of the H4L fragments to be precipitated by anti-
H4L1–256 was tested. In Fig. 3B, it can be seen that H4L
1–99, 1–125, 1–195, and 52–195 can be precipitated, in
vitro. Note that the efficiency of precipitation of 52–195
was less than the others. Importantly, H4L100–195 is not
precipitated efficiently by this antibody, indicating that
strong epitopes recognized by anti-H4L1–256 reside in the
N-terminal 99 amino acids. In an attempt to confirm
these observations, nonradioactive H4L fragments were
tested for their ability to block anti-H4L1–256 and prevent
precipitation of 35S-H4L1–195. Nonradioactive H4L frag-
ments were synthesized by coupled in vitro transcription/
translation in the absence of isotope. The level of radio-
active H4L fragment synthesis was evaluated by fluorog-
FIG. 1. Antibody inhibition of preinitiation complex activity. A. The bead-bound template employed contains a strong early promoter, P, which directs
transcription through a 20-nucleotide G-less cassette followed by three G residues in the nontemplate strand. Extracts prepared from cells infected
with either a ts mutant virus, C50, under nonpermissive conditions, B, or with wild-type virus, C, were pretreated with anti-H4L1–256. Bead-bound
preinitiation complexes were isolated and their ability to direct RNA synthesis (G21) was measured by autoradiography of gel-separated RNA.
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raphy of gel-separated samples. The amount of
nonradioactive H4L fragment was assumed to be the
same as the radioactive protein. In Fig. 3C it can be seen
that H4L1–195 readily competes, as expected. Importantly,
H4L1–99 competes virtually completely demonstrating that
the strong epitopes recognized by anti-H4L1–256 reside in
the first 99 amino acids of H4L. Since H4L52–195 offers no
competition, we can conclude that one or more strong
epitopes reside in H4L1–51. Titration of H4L1–99 and
H4L52–195 with anti-H4L1–256 demonstrates that the affinity
for the N-terminal site is at least 10-fold stronger than the
site between 52 and 99, in H4L52–195 (data not shown). To
further localize the strong epitopes, several clustered
charge to alanine, and bulky hydrophobic amino acids to
alanine derivatives of H4L1–195 were tested for their ability
to be precipitated by anti-H4L1–256. Mutations constructed
throughout the H4L1–195 fragment were tested. Only one
clustered mutation was altered in antibody binding. Sub-
stitution of Y18, L19, L20 with alanine in H4L1–195 Mut 18
reduced antibody precipitation, indicating that this region
contains part of the antibody recognition site, Fig. 3D.
Furthermore, change of Y18 to alanine alone resulted in
a severe loss of recognition while substitution of either
L19 or L20 had less effect on antibody binding. Due to its
lower affinity, H4L52–195 was not efficiently precipitated at
the antibody concentration employed, which was 10% of
that used above in Fig. 3B.
Anti-H4L1–256 does not inhibit preformed preinitiation
complexes
In order to determine whether anti-H4L1–256 inhibits the
formation of the active PIC or the activity of preformed
PICs, PICs were prepared by incubation of bead-bound
FIG. 2. Preincubation of anti-H4L1–256 with H4L fragments prevents antibody inhibition of PIC activity. Anti-H4L1–256 was preincubated with various
H4L fragments. H4L fragments were expressed as N-terminal his6 fusion proteins by induction of pET30 containing E. coli HMS(174)DE3. The antibody
preincubation was mixed with infected cell extracts and further incubated. After incubation with a bead-bound template, the bead-bound binary
complexes were isolated and their ability to direct RNA synthesis was measured. (A) anti-H4L1–256 was preincubated with H41–256 or H4L1–195. (B)
anti-H4L1–256 was preincubated with H41–99 or H41–125.
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FIG. 3. Anti-H4L1–256 binds to epitopes in amino acids 1–99. (A) Arrows indicate the map positions of the H4L fragments employed in these analyses.
(B) The ability of anti-H4L1–256 and anti-H4L568–795 to immunoprecipitate H4L fragments was tested. Two microliters of a 1/10 dilution of crude rabbit
polyclonal antiserum was employed. 35S-met-labeled H4L fragments were incubated with either antibody and the level of precipitation was evaluated
by gel electrophoresis. I, 50% input protein. (C) The ability of specific H4L fragments to compete with 35S-met-labeled H4L1–195 binding to anti-H4L1–256
was tested. 35S-met and nonradioactive proteins were prepared by coupled in vitro transcription and translation and mixed prior to antibody addition.
Precipitation was measured by fluorography of SDS gel-separated samples. (D) The ability of anti-H4L1–256 to precipitate wild-type or site-specific
mutations of H4L1–195 was tested as above. Two microliters of a 1/100 dilution of crude antiserum was used. The minor faster migrating radioactive
component is likely to be formed by premature translation termination. T, 50% of input, I, immune serum, P, preimmune serum.
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template with wild-type virus-infected cell extracts. Iso-
lated template-bound PICs were incubated with the set
of purified anti-H4L antibodies and after 30 min the
treated PICs were assayed for RNA synthesis activity by
the addition of nucleoside triphosphates. In Fig. 4 it can
be observed that none of the antibodies affected the
level of RNA produced by the antibody-treated isolated
PICs. These results are in agreement with the prior
observations (Ahn et al., 1994; Deng and Shuman, 1994)
demonstrating, anti-H4L antibodies exert their negative
affect by prevention of active PIC formation rather than
the activity of preformed PICs.
H4L fragments directly inhibit PIC activity
Preincubation of anti-H4L antibodies with H4L1–256 and
H4L1–195 failed to restore 100% transcription. Rather, at high
levels, the H4L fragments reduced the observed RNA syn-
thesis, Fig. 2A. In contrast, however, for H4L1–125 and H4L1–99,
maximal RNA synthesis was observed at high fragment
levels, Fig. 2B. One possible explanation for the observed
reduction is a direct inhibition of PIC formation by the longer
N-terminal H4L fragments. To test for a direct inhibition of
PIC activity by N-terminal his6 fusions of H4L, infected cell
extracts were incubated with increasing concentrations of
H4L fragments during the initial PIC assembly step. After
PIC formation, the beads were collected and washed and
PIC activity was assayed. In Fig. 5, it can be seen that both
H4L1–256 an H4L1–195 directly inhibit PIC activity. In effect, the
longer N-terminal H4L fragments act as dominant-negative
mutants, in vitro. However, H4L1–125 and H4L1–99 are far less
inhibitory (data not shown), indicating either that they lack a
region of the H4L protein required to bind to the factor(s)
needed for PIC formation or that these truncations fail to
adopt the normal H4L protein conformation resulting in
their inability to bind to the needed PIC forming factors. This
observation supports the notion that the N-terminal region
of H4L between amino acids 1 and 195 interacts with one
or more factors required for PIC formation. It is noteworthy
that the same H4L fragments fail to inhibit transcription
termination, in vitro (data not shown).
NPHI does not prevent anti-H4L1–256 inhibition of PIC
activity
Antibody inhibition of early gene transcription termina-
tion was observed only in extracts prepared from C50
virus-infected cells, which lack active NPHI (Christen et
FIG. 4. Antibodies do not inhibit transcription catalyzed by preformed
bead-bound preinitiation complexes. Wild-type virus-infected cell ex-
tracts were employed to generate bead-bound preinitiation complexes.
The PICs were further incubated with antibodies raised against various
regions of H4L and were then tested for their ability to support G21 RNA
synthesis.
FIG. 5. H4L fragments directly inhibit PIC activity. Extracts prepared from C50 virus-infected cell extracts were preincubated with his6-H4L
fragments prior to the addition of the bead-bound template. After further incubation, the bead-bound complexes were isolated and tested for their
ability to support G21 RNA synthesis.
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al., 1998), and was prevented by the presence of NPH I
prior to antibody addition to the infected cell extract.
However, anti-H4L1–256 clearly inhibits PIC activity in both
wild-type and mutant virus-infected cell extracts, Figs. 1B
and 1C, indicating that the binding of the antibody and
NPH I to H4L is not mutually exclusive. In order to further
evaluate the effect of NPH I on the ability of anti-H4L1–256
to inhibit PIC activity, extracts prepared from wild-type
virus-infected cells were compared to C50-infected cells
in the presence or absence of additional NPH I. NPH I
was added to a level that is at least 20 times the amount
required for maximal transcription termination, in vitro
(Christen et al., 1998). In Fig. 6 it can be seen that in all
cases, anti-H4L1–256 inhibits PIC activity indicating that
binding of NPH I and anti-H4L1–256 to H4L is not mutually
exclusive. Furthermore, this indicates that the sites on
H4L responsible for transcription initiation and NPHI
binding are different.
Antibody inhibition of early gene transcription
termination requires antibody binding to H4L amino
acids 1–99
Prior results showed that inhibition of early gene tran-
scription termination required antibody binding to one or
more epitopes in H4L1–195 (Mohamed and Niles, 2001). To
refine the location of the antibody-binding site, H4L frag-
ments 1–125 and 1–99 were tested for their ability to
prevent antibody inhibition of transcription termination. In
Fig. 7, it can be seen that preincubation of anti-H4L1–256
with H4L1–125 and H4L1–99 prevents antibody inhibition of
early gene transcription termination, demonstrating that
antibody binding to H4L between amino acids 1 and 99
is responsible for inhibiting both PIC activity and early
gene transcription termination.
Antibody binding to a site containing Y18 inhibits both
PIC activity and transcription termination
H4L1–99 binding to anti-H4L1–256 protects against anti-
body inhibition of both PIC activity and early gene tran-
scription termination. At least two epitopes are recog-
nized by the polyclonal antiserum in H4L1–99, a strong site
containing Y18 and a weak site between amino acids 52
and 99. To determine whether antibody binding to a
single epitope is responsible for inhibition of both steps
in transcription, Mal E fusions of wild-type H4L1–195 or
H4L1–195 containing a Y18, L19, L20 mutation were tested
for their ability to prevent antibody inhibition. In Fig. 8, it
can be seen that in comparison to the wild-type Mal
E-H4L1–195, Mal E-H4L1–195 containing alanine substitu-
tions of amino acids 18 to 20 is reduced fourfold in its
ability to prevent inhibition of transcription termination
and PIC formation, demonstrating that antibodies bind-
ing to this site are responsible for inhibiting both steps.
DISCUSSION
The H4L protein is a component of the minority frac-
tion of the virion RNA polymerase (Ahn et al., 1994; Ahn
and Moss, 1992). Prior studies demonstrated that only
the H4L-containing RNA polymerase is active in early
gene transcription (Ahn et al., 1994; Deng and Shuman,
1994). Further analyses showed that H4L plays a role in
FIG. 6. NPH I does not affect the ability of anti-H4L1–256 to inhibit PIC activity. Extracts prepared from either wild-type virus or C50 virus-infected cells
were employed. Extracts were tested either alone or in the presence of additional NPHI. The ability of anti-H4L1–256 to inhibit G21 RNA synthesis on
bead-bound complexes isolated from these extracts was measured.
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transcription initiation and termination (Mohamed and
Niles, 2000, 2001) but not elongation. Thus, H4L is a
unique RNA polymerase subunit that functions at each
end of the transcription pathway. Antibodies raised
against the N-terminal 40% of H4L inhibit transcription
initiation (Ahn et al., 1994; Deng and Shuman, 1994).
Evidence points to the prevention of preinitiation com-
plex formation by the antibodies suggesting that H4L
serves as a site for interaction with one or more essen-
tial transcription initiation factors. One likely candidate is
VETF a heterodimeric viral-encoded protein that serves
as an early promoter binding factor (Broyles et al., 1988).
A different polyclonal antiserum was employed in the
studies reported herein to further investigate the role of
H4L in viral transcription. By evaluating the ability of a set
of H4L fragments to block the antibody inhibition of PIC
activity the inhibitory antibody-binding site was mapped
to H4L amino acids 1–99. Further direct binding studies
and competition analyses indicated that the strong anti-
body-binding site(s) mapped to the N-terminal 51 amino
acids. Analyses of site-specific mutations defined Y18 as
a component of the epitope that binds the antibody with
greatest affinity. Titration of anti-H4L1–195 demonstrated
that the antibodies that inhibited both initiation and ter-
mination exhibited a similar affinity for H4L (data not
shown). Furthermore, since H4L1–195 possessing alanine
substitutions of amino acids 18 to 20 exhibited both
decreased affinity for anti-H4L1–195 and reduced ability to
block antibody inhibition of PIC activity and transcription
termination, antibodies that bind to a site containing Y18
must be responsible for inhibition of both steps in tran-
scription.
These studies define the antibody-binding site(s) on
H4L1–195 but reveal little about the mechanism of inhibi-
tion of PIC activity. One can imagine that the bound
antibody directly prevents H4L binding to one or more
required factors, including VETF. Alternatively, the bound
antibody could alter the conformation of H4L preventing
factor binding at a site that is not occluded by the
antibody. Since H4L1–195 acts as a dominant negative
mutation and directly inhibits PIC activity, the factor-
binding site(s) is likely to reside within the first 195 amino
acids. The inability of H4L1–125 and H4L1–99 to inhibit di-
rectly indicates that the factor-binding site may lie be-
FIG. 7. Short H4L fragments block the ability of anti-H4L1–256 to inhibit early gene transcription termination, in vitro. Extracts were derived from ts
C50 virus-infected cells, which lack NPH I. Ternary complexes containing the template, RNA polymerase, and G21 RNA were prepared after the
addition of a bead-bound template, UTP, ATP, [32P]CTP, and 3-O-methyl-GTP. Anti-H4L1–256 was preincubated with varying concentrations of H4L1–125
or H4L1–99 prior to addition to the isolated ternary complexes. RNA synthesis was continued by the addition of four deoxynucleoside triphosphates
and the level of both the full-length runoff RNA (FL) and the terminated RNA (term) was measured after gel electrophoretic separation of the RNA
products.
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tween amino acids 125 and 195. However, these data do
not exclude the possibility that the conformation of
H4L1–99 or H4L1–125 is altered, resulting in the loss of the
factor-binding competence. The most likely candidate for
an H4L-binding partner is VETF. However, a direct inter-
action between N-terminal region of H4L and either sub-
unit of VETF was not observed in a yeast two-hybrid
analysis (Deng and Shuman, 1994). Furthermore, we
failed to observe an interaction between the N-terminal
region of H4L with VETF subunits either alone or in
combination in a series of pulldown analyses, or sepa-
rately in a yeast two-hybrid study (unpublished data).
One must consider the possibility that VETF does not
bind directly to H4L. Alternatively, either VETF binding
requires additional RNA polymerase subunits or one or
more additional factors are employed in stable PIC for-
mation.
Since cordycepin triphosphate does not inhibit the
assembly of a bead-bound template PIC in these studies,
the synthesis of a short transcript is not required to form
a stable complex. This is consistent with the results of Li
and Broyles (Li and Broyles, 1993) but in contrast to
observations reported by others (Ahn et al., 1994; Deng
and Shuman, 1994) who employed purified RNA polymer-
ase and VETF. In these experiments, it is not clear how
efficient the PIC assembly is. Perhaps stable PICs form
on only a small fraction of templates, thus permitting
their analyses in the presence of an excess of free
template. Alternatively, since these studies employ a
crude extract of virus-infected cells as the source of viral
proteins, one or more factors may be present that en-
hances the formation of stable PICs. The inability of
antibodies to inhibit isolated preformed PICs demon-
strates that the antibodies inhibit the formation and not
the transcription activity of the PIC, in agreement with
prior observations (Ahn et al., 1994; Deng and Shuman,
1994).
The N-terminal 195 amino acids of H4L were shown to
be required for transcription termination, as well (Mo-
hamed and Niles, 2000, 2001). Further analyses demon-
strated that the inhibitory antibody binds between amino
acids 1–99, indicating that the same bound antibody
inhibits both transcription initiation and termination. Prior
binding of NPH I was shown to prevent antibody inhibi-
FIG. 8. H4L1–195 (Y18A, L19A, L20A) exhibits reduced ability to prevent anti-H4L1–195 inhibition of PIC activity and transcription termination.
Anti-H4L1–195 was preincubated with different concentrations (pmol) of either wild-type Mal E-H4L1–195 or a mutant form in which amino acids 18 to 20
were substituted for alanine. A 250 ng of purified IgG fraction was employed in these studies. The blocked antibodies were tested for their ability to
inhibit either PIC activity or transcription termination. The percentage of PIC activity restored upon incubation of the antibody with the mal E fusion
proteins was calculated using the control lane in the lower panel.
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tion of termination (Mohamed and Niles, 2001). This
indicated that the binding of antibody and NPH I was
mutually exclusive. However, it is clear from the present
studies that the presence of NPH I does not influence the
ability of the antibody to inhibit active PIC formation,
indicating that both antibody and NPH I can bind simul-
taneously to H4L. Thus the antibody does not prevent
NPH I binding to H4L, so exclusion of NPH I from the
termination complex cannot explain the antibody inhibi-
tion of termination. One model may explain these obser-
vations. Prebound NPH I may stabilize a conformation of
H4L active in termination without preventing antibody
binding. However, antibody bound in the absence of
NPH I induces an inactive conformation of H4L, which
cannot be restored upon NPH I binding. In all cases,
antibody binding inhibits PIC activity. Further analyses
are required to evaluate the validity of this model.
It is remarkable that a limited region of a single RNA
polymerase subunit is required for both early gene tran-
scription initiation and termination. This single subunit
provides the specificity required for each of these essen-
tial transcription events. A definition of its role in tran-
scription initiation awaits the identification of its binding
partner. Although binding of NPH I to this segment of
H4L is essential for transcription termination and release
(Mohamed and Niles, 2000, 2001), the mechanism of
coupling ATP hydrolysis to the dissolution of the ternary
complex remains to be elucidated.
MATERIALS AND METHODS
Cells and viruses
Wild-type (WT) vaccinia virus strain WR and the tem-
perature-sensitive (ts) mutant virus, C50, were propa-
gated in BSC40 African green monkey cells at 37°C, or
the permissive temperature for ts mutants, 31°C, respec-
tively, as described (Condit and Motyczka, 1981; Condit
et al., 1983). Crude extracts of virus-infected cells were
prepared by freeze/thaw, and infectious virus titer was
determined by plaque assay on BSC40 cells at the per-
missive temperature, 31°C, and the nonpermissive tem-
perature, 40°C.
Purification of anti-H4L antibodies
Polyclonal rabbit antisera were prepared against seg-
ments of the H4L subunit of the virion RNA polymerase,
representing amino acids 1–256, 258–556, and 568–795
(Mohamed and Niles, 2001). The IgG fraction of each
antiserum was isolated using Affi-gel protein A MAPS II
kit (Bio-Rad. Protein A-agarose was packed in a column
(10 ml Poly-Prep Column, Bio-Rad) and washed with the
binding buffer provided with the kit. One milliliter of
antiserum was diluted 1:1 with the binding buffer and
loaded onto a protein A-agarose column. The unbound
fraction of the serum was washed off the column, and the
bound fraction (IgG) subsequently eluted with the elution
buffer, pH 2.8. The eluates were collected in 1-ml frac-
tions in tubes containing 200 l 0.1 M Tris-HCl, pH 8.0, to
neutralize the eluates. The column effluent was moni-
tored spectrophotometrically at 280 nm in order to detect
the protein peaks. Fractions were pooled, aliquoted, and
stored at 80°C.
Immunoprecipitation
For each immunoprecipitation, 5 l of the IgG fraction
(0.7 mg/ml) was employed with 1 l of the 35S-labeled
transcription translation product in a total incubation of
200 l. The reaction was incubated at 4°C overnight with
constant rocking. The antibodies were collected by the
addition of 20 l protein A-agarose and the precipitate
was washed four times as described (Springer, 1987).
The final pellet was resuspended in sample buffer,
boiled, and applied to a polyacrylamide SDS gel. The gel
was then soaked in 1 M salicylic acid for 30 min and
dried and fluorography was then performed at 80°C.
For the immunoprecipitation competition experiment, 1
l of the IgG fraction (0.07 mg/ml) was added to a 200-l
incubation containing 1 l of the 35S-H4L1–195, prepared
by in vitro transcription and translation, in the presence
or absence of increasing volumes of the cold transcrip-
tion translation product of H4L fragments 1–195, 1–99,
1–125, 100–195, and 52–195.
Transcription extracts
Extracts of virus-infected cells were prepared by lyso-
lecithin treatment, as described (Condit et al., 1996).
A549 cells were infected with either wild-type or ts mu-
tant viruses at a multiplicity of infection (m.o.i.) of 15, at 37
or 31°C, respectively. In the case of the ts mutant virus,
after 24 h, the medium was removed and replaced with
40°C medium containing 100 g/ml of cycloheximide.
After a further 24 h at 40°C, cells were washed and
treated with 250 g/ml lysolecithin and extracts pre-
pared. This procedure permits the initial synthesis of
active NPH I, which is required for intermediate and late
gene expression (Kunzi and Traktman, 1989). After
switching to 40°C, the endogenous NPH I is inactivated
and cycloheximide prevents the synthesis of new protein
(Christen et al., 1998).
Preinitiation complex activity assay
Construction of the G21(TER29)A78 plasmid contain-
ing a vaccinia early promoter was described by Deng et
al. (1996). This plasmid was generously provided by Dr.
Stewart Shuman. The prototype G21(TER29)A78 tran-
scription unit consists of a synthetic early promoter fused
to a 20-nucleotide G-less cassette, which is flanked by a
run of three G residues at positions 21 to 23. RNA
synthesis in the absence of GTP and the presence of
3-O-methyl-GTP yields a 21-base product that can be
151ANTIBODIES AGAINST H4L INHIBIT TRANSCRIPTION
identified by gel electrophoresis. A 57-nucleotide A-less
cassette lies downstream of the G-less cassette and is
flanked at its 3 end by four A residues at positions 78
to 81. A termination signal, TTTTTTTTT, lies within the
A-less cassette, spanning position 29 to 37. The
biotinylated 324-bp DNA template was amplified by PCR
employing a 5 biotin tag on the upstream primer and
isolated by preparative agarose gel electrophoresis. The
purified DNA fragment was then immobilized to strepta-
vidin-coated magnetic beads (Dynabeads M280; Dynal)
as described (Mohamed and Niles, 2000).
In order to form the preinitiation complex, the bead-
bound template (typically, 100 fmol) was incubated for 15
min at room temperature with an extract prepared from
cells that were either infected with C50 ts mutant virus
that lacks NPHI (Christen et al., 1998) or with wild-type
virus. After incubation, the template was isolated and
washed with 20 l of transcription buffer to remove
loosely bound material. The level of active PIC was
assayed by incubation for 30 min at 30°C with 1 mM ATP,
10 Ci [32P]CTP (800 Ci/mmol), 0.1 mM UTP, and 0.625
mM 3OMeGTP, and after gel electrophoresis, the RNA
observed by autoradiography.
To assess the ability of anti-H4L antibodies to inhibit
early gene PIC activity, extracts prepared from cells in-
fected with either wild-type virus or C50 ts mutant virus
were preincubated for 15 min on ice with IgG raised
against different regions of H4L. When indicated, the IgG
fractions were preincubated with H4L fragments for 20
min on ice, prior to incubation with the infected cell
extracts. After incubation of the bead-bound template
with the antibody-treated infected cell extract for 15 min
at room temperature, the template was isolated and
washed to remove loosely bound material. The level of
active PIC was assayed by incubation for 30 min at 30°C
as described above, and RNA was observed by gel
electrophoresis.
In order to test for the ability of the H4L fragments to
inhibit the formation of an active PIC directly, extracts
prepared from virus-infected cells were incubated with
different amounts of H4L fragments for 20 min on ice.
After incubation of the bead-bound template with the
pretreated infected cell extract for 20 min on ice, the
template was isolated and washed to remove loosely
bound material. The level of active PIC was assayed as
described above.
Addition of [32P]CTP to an infected cell extract results
in end labeling of endogenous tRNA, which provides a
variable background of contaminating RNA in the gel
analysis. On occasion, background labeling was re-
duced by preincubating the extract with 1 M CTP for 15
min at room temperature, prior to the transcription assay.
Although this step reduces the specific activity of the
isotope about twofold, it dramatically reduces the back-
ground radioactivity.
Transcription termination assay
The bead-bound (B) template (typically, 100 fmol) was
first incubated with 6 l of C50 or WT virus-infected cell
extracts, in the presence of 20 mM Tris-HCl, pH 8, 6 mM
MgCl2, 2 mM dithiothreitol, 1 mM ATP, 10 Ci [
32P]CTP
(800 Ci/mmol), 0.1 mM UTP, and 0.625 mM 3OMeGTP for
30 min at 30°C to synthesize the G21 transcript. The
ternary complex was isolated, washed in 20 l of tran-
scription salts, resuspended in 5 l of transcription salts,
and incubated in the presence or absence of the IgG
fractions, and NPH I. When indicated, the IgG fractions
were preincubated with H4L fragments for 20 min on ice,
prior to incubation with the ternary complexes. The ter-
nary complexes were collected by centrifugation and
resuspended and termination was then assessed after
elongation for 30 min at 30°C in the presence of 1 mM
UTP, 1 mM GTP, 1 mM CTP, and 1 mM ATP, and the
presence or absence of VTF and NPH I. Elongation of the
nascent RNA chains beyond the arrest site at G21 de-
pended on removal of the blocking 3OMeGMP moiety
by the hydrolytic activity intrinsic to the vaccinia RNA
polymerase elongation complex (Hagler and Shuman,
1993). Elongation of the transcript beyond the G21 posi-
tion, in the presence of all 4 NTPs, would yield a tran-
script of about 177 bases in length (FL). Greater than 90%
of the isolated ternary complexes were routinely elon-
gated in the second RNA synthesis reaction. Signal-
dependent termination would be expected to produce a
family of RNA products about 70 bases in length (Term).
Termination efficiency was calculated as the molar ratio
of terminated RNA to the sum of read-through and ter-
minated RNA.
Plasmids
pCITE-4a-H4L plasmid containing full-length H4L was
constructed by inserting an NcoI–SalI DNA fragment de-
rived from pET-14a-H4L (obtained from Dr. Stewart Shu-
man), containing the entire coding sequence of H4L, into
the NcoI–SalI-digested pCITE-4a. H4L retains a 5 His6-tag
encoded in pET-14a. pCITE-4a-H4L1–195 was constructed by
digesting the pCITE-4a-H4L plasmid with AccI and religa-
tion of the digested construct. pET-30a-H4L1–195 was con-
structed by excising the H4L DNA fragment from pCITE-4a-
H4L1–195 with NcoI and XhoI, and inserting it into pET-30a. A
series of truncations of the H4L1–195 fragment was con-
structed in both pCITE-4a and pET-30a plasmid vectors.
The coding sequence corresponding to H4L fragments
1–99, 1–125, 100–195, and 52–195 was PCR-amplified using
a proofreading polymerase Pfu. The amplified blunt-end
PCR fragments were ligated into pCR-Blunt II-TOPO plas-
mid vector and their sequences were determined to ensure
fidelity. The truncated H4L fragments were then excised
using NcoI–SalI restriction digestion and ligated into both
pCITE-4a and pET-30a, linearized with NcoI–SalI and NcoI–
XhoI, respectively.
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pET30a derivatives of H4L were constructed and ex-
pressed in Escherichia coli HMS174(DE3) upon IPTG
induction. Fragments were purified from S100 fractions
by chromatography on nickel agarose, analyzed by gel
electrophoresis, and quantified by absorbancy at 280 nm
using extinction coefficients estimated by the GCG Pep-
tide Sort program (Mohamed and Niles, 2001). Mal E
fusion derivatives of H4L were constructed in pMalc2
and expressed in E. coli upon IPTG induction. Fusion
proteins were purified from S100 fractions by chromatog-
raphy on amylose resin. Proteins were evaluated by gel
electrophoresis and the protein concentrations were es-
timated by A 280 absorbancy using extinction coefficients
determined as stated above.
In vitro transcription/translation
A Novagen Single Tube Protein system 3 (STP3) was
used for the in vitro synthesis of both cold and 35S-
labeled proteins directly from DNA templates containing
T7 RNA polymerase promoter. The DNA template (typi-
cally 0.5 g) was transcribed in 10 l at 30°C for 15 min
followed by the addition of 40-l translation mix contain-
ing either cold or 35S-labeled methionine and incubated
for a further 60–90 min.
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